On February 12, 2026, the first patient was successfully randomized in the exploratory trial "SO‑002 for the Safety and Efficacy in ALS," led by Principal Investigator Professor Shang Huifang, Department of Neurology, West China Hospital, Sichuan University, with Chengdu West China Clinical Research Center Co., Ltd. serving as the Contract Research Organization (CRO).
ALS is a fatal neurodegenerative disease with an average survival of only 40 months, and current treatments have limited efficacy. SO‑002 is a low‑molecular‑weight compound identified by SOCIUM Inc. (Japan) through AI‑based screening; preclinical studies have shown that SO‑002 effectively reduces neuronal death.
This exploratory trial aims to evaluate the safety and preliminary efficacy of SO‑002 in ALS patients. As the collaborating CRO, Chengdu West China Clinical Research Center Co., Ltd. provided full‑cycle project management and worked closely with the study team to efficiently facilitate patient screening, informed consent, and randomization.
The successful randomization of the first patient validates the feasibility of the study procedures and demonstrates the strong collaborative efficiency among the sponsor, CRO, and investigators. The study continues to recruit eligible ALS patients, and our team remains committed to rigorous and professional standards, contributing clinical research "acceleration" to the development of new drugs for rare neurological diseases.
